Compare BANF & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANF | CORT |
|---|---|---|
| Founded | 1984 | 1998 |
| Country | United States | United States |
| Employees | 2260 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | N/A | 2001 |
| Metric | BANF | CORT |
|---|---|---|
| Price | $115.91 | $83.44 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $124.00 | $96.50 |
| AVG Volume (30 Days) | 125.5K | ★ 983.7K |
| Earning Date | 04-16-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $6.10 | $26.08 |
| Revenue Next Year | $3.92 | $26.98 |
| P/E Ratio | $16.38 | ★ N/A |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $101.48 | $28.66 |
| 52 Week High | $138.15 | $91.00 |
| Indicator | BANF | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 63.45 | 87.00 |
| Support Level | $106.29 | $68.20 |
| Resistance Level | $122.05 | $90.00 |
| Average True Range (ATR) | 2.50 | 3.21 |
| MACD | 0.70 | 0.96 |
| Stochastic Oscillator | 92.49 | 94.64 |
BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Its Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.